Holen Sie sich die Stockscreener-App
0.5832
0.59%
0.0034
Handel nachbörslich:
.60
0.0168
+2.88%
Schlusskurs vom Vortag:
$0.5798
Offen:
$0.6099
24-Stunden-Volumen:
520.25K
Relative Volume:
0.35
Marktkapitalisierung:
$174.68M
Einnahmen:
$54,000
Nettoeinkommen (Verlust:
$-210.26M
KGV:
-0.7382
EPS:
-0.79
Netto-Cashflow:
$-159.01M
1W Leistung:
-0.17%
1M Leistung:
-6.09%
6M Leistung:
-63.09%
1J Leistung:
-69.62%
1-Tages-Spanne:
$0.5545
$0.6099
1-Wochen-Bereich:
$0.5545
$0.6522
52-Wochen-Spanne:
$0.5505
$3.2556
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Firmenname
Lyell Immunopharma Inc
Sektor
Branche
Telefon
650 695-0677
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Vergleichen Sie LYEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
0.5832 | 174.68M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-30 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-06-27 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | BofA Securities | Buy |
| 2021-07-12 | Eingeleitet | Goldman | Buy |
| 2021-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-12 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten
Lyell Immunopharma Faces Nasdaq delisting over share price - MSN
Lyell Immunopharma Faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Barclays PLC Has $332,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma price target lowered to 60c from $1 at BofA - MSN
Lyell Immunopharma stock hits 52-week low at $0.58 - Investing.com India
Lyell to Highlight Vision for its Next-Generation CAR - GlobeNewswire
Lyell's IMPT-314 Cancer Therapy Shows 94% Response Rate, Plans Pivotal Trials for Lymphoma - StockTitan
Jane Street Group LLC Buys 111,917 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Barclays PLC Has $332,000 Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) - Yahoo Finance
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) - Yahoo Finance
State Street Corp Has $5.37 Million Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell' - GuruFocus.com
Charles Schwab Investment Management Inc. Trims Stock Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Shares Sold by Fmr LLC - Defense World
Fmr LLC Has $1.41 Million Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - MarketBeat
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround - Yahoo Finance
Lyell Immunopharma stock hits 52-week low at $0.85 By Investing.com - Investing.com Australia
Lyell Immunopharma stock hits 52-week low at $0.85 - Investing.com India
Lyell's IMPT-314 Cancer Therapy Shows Stunning 94% Response Rate in Lymphoma Trial - StockTitan
Lyell Presents Positive Initial Clinical Data from the - GlobeNewswire
Form 424B5 Lyell Immunopharma, Inc. - StreetInsider.com
Intech Investment Management LLC Acquires New Shares in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
SEC Form S-3 filed by Lyell Immunopharma Inc. - Quantisnow
Lyell Immunopharma Reports Resignation of Board Member - Defense World
Lyell Immunopharma Director Hans bishop resigns - Investing.com
Lyell Immunopharma Director Hans bishop resigns By Investing.com - Investing.com Australia
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know - MSN
HC Wainwright Reiterates "Neutral" Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts - Benzinga
Lyell Immunopharma: Q3 Earnings Snapshot - AOL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 - The Manila Times
Lyell Immunopharma Reports Q3 2024 Financial Results - TipRanks
Lyell Announces Presentation of Initial Clinical Data from - GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Lyell's Novel CAR T-Cell Therapy Data to Be Unveiled at ASH 2024 Following FDA Fast Track Status | LYEL Stock News - StockTitan
Vanguard Group Inc's Strategic Reduction in Lyell Immunopharma I - GuruFocus.com
Lyell shares down as BofA double downgrades to Sell - MSN
Lyell Immunopharma (NASDAQ:LYEL) Downgraded to “Underperform” Rating by Bank of America - Defense World
Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):